| Drug General Information |
| Drug ID |
D0UL2H
|
| Former ID |
DIB003588
|
| Drug Name |
Androgen restored contraceptive
|
| Synonyms |
A-ENDO; ARC, Pantarhei; Androgen restored contraceptive (oral, contraception); Androgen restored contraceptive (oral, contraception), Pantarhei; Drug combination (oral, endometriosis), Pantarhei; Androgen/estrogen/progestogen combination (oral, endometriosis), Pantarhei; Dehydroepiandrosterone/estrogen/progestogen combination (oral, endometriosis), Pantarhei
|
| Indication |
Contraception [ICD10:Z30]
|
Phase 2 |
[1]
|
|---|
| Company |
Pantarhei Bioscience BV
|
| Target and Pathway |
| Target(s) |
Androgen receptor |
Target Info |
Agonist |
[2]
|
|---|
| Progesterone receptor |
Target Info |
Agonist |
[2]
|
| Estrogen receptor |
Target Info |
Agonist |
[3]
|
|
KEGG Pathway
|
Oocyte meiosis
|
|
Pathways in cancer
|
|
Prostate cancerhsa04114:Oocyte meiosis
|
|
Progesterone-mediated oocyte maturationhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
EGFR1 Signaling Pathway
|
|
AndrogenReceptor Signaling Pathway
|
|
FSH Signaling PathwayNetPath_25:FSH Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Coregulation of Androgen receptor activity
|
|
Regulation of Androgen receptor activity
|
|
Nongenotropic Androgen signaling
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FOXA1 transcription factor network
|
|
Notch-mediated HES/HEY networkanthraxpathway:Cellular roles of Anthrax toxinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Reactome
|
Nuclear Receptor transcription pathway
|
|
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3R-HSA-1251985:Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
|
Androgen receptor signaling pathwayWP34:Ovarian Infertility Genes
|
|
Signaling by ERBB4
|
|
Nuclear ReceptorsWP712:Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
JAK/STAT
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
| References |
| REF 1 | Treatment outcome in endodontics-the Toronto Study. Phase II: initial treatment. J Endod. 2004 May;30(5):302-9. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Pantarhei Bioscience . |
|---|
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). |
|---|
